WP-1303 Phase 3 combination study

A combination study on WP-1303 or placebo and latanoprost ophthalmic solution in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224837

Enrollment

280

Registered

2019-08-20

Start date

2019-09-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open-angle glaucoma, ocular hypertension

Interventions

investigational material(s) Generic name etc : WP-1303 INN of investigational material : - Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational mater

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with POAG or OH. IOP is less than 35 mmHg for both eyes. IOP aftre latanoplost treated is greater than or equal to 18mmHg.

Exclusion criteria

Exclusion criteria: Patients who have visual acuity of less than 0.3. Presence of active eye disease (eg., uveitis, ocular infection, severe dry eye). Pregnant women, lactating women or women who desire to be pregnant. Patients who is judged inappropriate to participate in the study by investigator or sub-investigator.

Design outcomes

Primary

Measure	Time frame
safety efficacy efficacy:intraocular pressure safety:adverse event and adverse drug reaction	—

Secondary

Measure	Time frame
efficacy efficacy:intraocular pressure	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026